Connect with us

Media & Technology

INND (InnerScope Hearing Technologies) Powerful Reversal as Co Prepares to Launch New Smartphone Controlled Self-Fitting Rechargeable Hearing Aids

Published

2 years ago

on

INND (InnerScope Hearing Technologies) is making an explosive move up the charts since making a massive reversal after a brief dip below $0.02 on Friday. The stock has massive liquidity and legions of new shareholders that were once again heavily accumulating late last week. INND has already proven its a serious runner making a spectacular move up the charts over the past few months from triple zeroes to highs of $0.098 per share highs. Last Wednesday the Company reported it has completed and updated the FDA Medical Device Registration for Class II Hearing Aid, Air Conduction with Wireless Technology. The completion of the FDA Medical Device Registration (Registration Establishment Number 3014545266) for InnerScope’s Nexus HD, HearIQ ITC, HearIQ4, and the HearIQ20, its newest family of rechargeable hearing aid devices, and as well as its Alpha Series of hearing aid devices. The FDA Medical Device Registration is one of the last steps needed for InnerScope to launch its latest in Direct-to-Consumer Hearing Aid Technology with its Smartphone App-Controlled Self-Fitting – Self-Adjusting Rechargeable Hearing Aids with built-in Professional Remote Programming & Support Service. Penny stock speculators accumulating INND are looking for a swift return to previous highs; a break over $0.098 is confirmation of the next powerful leg up and a parabolic blue sky INND breakout. 

INND continues to make big moves as it prepares to launch its New Smartphone Controlled Direct-to-Consumer Self-Fitting-Self-Adjusting Rechargeable Hearing Aids with built-in Professional Remote Programming & Support Service. InnerScope plans on launching its Self-Fitting Hearing Aids on multiple online platforms with the upcoming announcements of several retailers and on its own newly revamp NoHassleHearing.com (expected to be finished by the end of the month). In preparation for the launch, InnerScope has ramped up its inventory of its Self-Fitting Hearing Aids and Hearing Products for the anticipation of generating over five hundred thousand dollars ($500,000) to InnerScope of sales revenue for the launch. Check out the app here. INND is well-positioned to directly benefit from the Over the Counter Hearing Aid Act which is expected to be enacted early this year. InnerScope’s Self-Fitting Hearing Aids deliver 21st Century hearing aid technology right to everyone’s fingertips just by using their smartphone at an affordable price. InnerScope’s Self-Fitting Hearing Aids empowers the user to take full control of their hearing health needs. InnerScope believes the solid foundation the Company has built over the last three years puts them in a prime position to be a leader in the emerging DTC/OTC hearing aid market. With InnerScope’s current and upcoming retail distribution/vendor sales channels producing consistent and ongoing revenue growth. 

InnerScope Hearing Technologies (OTC: INND) is a manufacturer, distributor, and retailer of FDA-Registered Direct-to-Consumer Self-Fitting–Self-Adjusting Hearing Aids, Self-Fitting–Self-Adjusting Personal Sound Amplifiers Products, Doctor-Formulated Dietary Hearing & Tinnitus Supplements, and Assorted Ear & Hearing Health-Related Products its mission is to improve the quality of life of the 70 million people in North America who suffer from hearing impairment and/or hearing-related issues. The management team of InnerScope is applying decades of industry experience and believes it is well-positioned to directly benefit from the Over the Counter Hearing Aid Act (expected to be enacted in early 2021). InnerScope with its Affordable Self-Fitting – Self-Adjusting Hearing Technology, combined with its innovative point of sale Hearing Screening Kiosks designed for consumers with mild-to-moderate hearing loss to purchase over-the-counter hearing aids without being seen by a hearing care professional.  

In February the Company reported it plans to launch its latest breakthroughs in Hearing Technology with its New Smartphone Controlled Direct-to-Consumer Self-Fitting-Self-Adjusting Rechargeable Hearing Aids with built-in Professional Remote Programming & Support Service.  With the launch of Self-Fitting Hearing Aids, InnerScope will be replacing all of its legacy hearing aid products that are either not rechargeable or requires separate remote control to make adjustments. The Self-Fitting Hearing Aids provides the consumers an easy, accurate, and straightforward way to fit themselves in under 5 minutes using their Smartphone. Moreover, InnerScope believes its Self-Fitting Hearing Aids deliver the same quality hearing experience and satisfaction for thousands of dollars less than a professionally in-office fitted hearing aid. InnerScope believes its DTC Self-Fitting Hearing Aids have the same capabilities to deliver a personalized hearing experience unique to an individual hearing needs, just as hearing aids are sold and fit by licensed hearing aid providers. The difference is InnerScope can provide this personalized hearing experience at 60% to 85% lower cost versus hearing aids sold and fit by licensed hearing aid providers. 

With the launch planned to begin spring of 2021, InnerScope as a wholesale vendor for Walmart will be updating its storefront on Walmart.com and other major online retailers for more enhanced visibility to achieve greater sales conversions. Concurrently, InnerScope is working on rolling out its Self-Fitting Hearing Aids and its other Hearing Products with major brick and mortar retailers starting Spring 2021.  

The Company is led by CEO Matthew Moore who literally grew up in the hearing health industry, with having internships and mentorships beginning with his Grandfather who has personally helped over 20,000 hearing- impaired patients in his private hearing aid practice since the 1940s. At the age of 10, Matthew was working in the Marketing Department of his parents private hearing aid practice. By the age of 22, Matthew became a full partner in his parents hearing aid business, which then grew to one of the largest private hearing aid practices in the United States with over 70 locations and over 40,000 customers in a 10-year period. Several years ago the family sold off the remaining locations for $14 million. As CEO of InnerScope, Mr. Moore has been making one big move after another recently forming distribution partnerships with Walmart, Sears, and other Big Box Retailers/Pharmacies as well as independent retailers and pharmacies for InnerScope’s Products and Services.  

Investor Sentiment in INND is high:

https://twitter.com/1wallstgatsby/status/1368752422814900237

To Find out the inside Scoop on INND Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

INND

INND could see significant growth and is well-positioned to directly benefit from the Over the Counter Hearing Aid Act which is expected to be enacted early this year. The hearing aids market is booming; According to a report from Fortune Business Insights the global hearing aids market is set to gain impetus from the increasing adoption of telehealth among audiologists to prevent patient traffic. The report further states that the market size was USD 8.99 billion in 2019 and is projected to reach USD 13.38 billion by 2027, exhibiting a CAGR of 8.2% during the forecast period. 

On March 3 INND announced it has completed and updated the FDA Medical Device Registration for Class II Hearing Aid, Air Conduction with Wireless Technology. The completion of the FDA Medical Device Registration (Registration Establishment Number 3014545266) for InnerScope’s Nexus HD, HearIQ ITC, HearIQ4, and the HearIQ20, its newest family of rechargeable hearing aid devices, and as well as its Alpha Series of hearing aid devices. The FDA Medical Device Registration is one of the last steps needed for InnerScope to launch its latest in Direct-to-Consumer Hearing Aid Technology with its Smartphone App-Controlled Self-Fitting – Self-Adjusting Rechargeable Hearing Aids with built-in Professional Remote Programming & Support Service. 

InnerScope plans on launching its Self-Fitting Hearing Aids on multiple online platforms with the upcoming announcements of several retailers and on its own newly revamp NoHassleHearing.com (expected to be finished by the end of the month). In preparation for the launch, InnerScope has ramped up its inventory of its Self-Fitting Hearing Aids and Hearing Products for the anticipation of generating over five hundred thousand dollars ($500,000) to InnerScope of sales revenue for the launch. 

Matthew Moore, CEO of InnerScope Hearing Technologies, commented, “completing FDA Medical Device Registration gives InnerScope a clear path for launching its Self-Fitting Hearing Aids. InnerScope’s Self-Fitting Hearing Aids will deliver 21st Century hearing aid technology right to everyone’s fingertips just by using their smartphone. Also, by cutting out the middleman (the hearing aid professional/provider), InnerScope can also deliver affordability to the customer without sacrificing hearing quality or satisfaction. InnerScope’s Self-Fitting Hearing Aids empowers the user to take full control of their hearing health needs.  Once the FDA publishes its final regulation for the Over the Counter Hearing Aid Act, InnerScope will submit its Self-Fitting Hearing Aids for the new FDA-OTC Medical Device Registration. We believe the solid foundation we built over the last three years has InnerScope in a prime position as a leader in the emerging DTC/OTC hearing aid market. With InnerScope’s current and upcoming retail distribution/vendor sales channels will produce consistent and ongoing revenue growth.” 

https://twitter.com/SalsTradingOTC/status/1368739881728499713

For More on INDD Subscribe Right Now!

INND (InnerScope Hearing Technologies) is making an explosive move up the charts since making a massive reversal after a brief dip below $0.02 on Friday. The stock has massive liquidity and legions of new shareholders that were once again heavily accumulating late last week. INND has already proven its a serious runner making a spectacular move up the charts over the past few months from triple zeroes to highs of $0.098 per share highs. Last Wednesday the Company reported it has completed and updated the FDA Medical Device Registration for Class II Hearing Aid, Air Conduction with Wireless Technology. The completion of the FDA Medical Device Registration (Registration Establishment Number 3014545266) for InnerScope’s Nexus HD, HearIQ ITC, HearIQ4, and the HearIQ20, its newest family of rechargeable hearing aid devices, and as well as its Alpha Series of hearing aid devices. The FDA Medical Device Registration is one of the last steps needed for InnerScope to launch its latest in Direct-to-Consumer Hearing Aid Technology with its Smartphone App-Controlled Self-Fitting – Self-Adjusting Rechargeable Hearing Aids with built-in Professional Remote Programming & Support Service. Penny stock speculators accumulating INND are looking for a swift return to previous highs; a break over $0.098 is confirmation of the next powerful leg up and a parabolic blue sky INND breakout.  INND continues to make big moves as it prepares to launch its New Smartphone Controlled Direct-to-Consumer Self-Fitting-Self-Adjusting Rechargeable Hearing Aids with built-in Professional Remote Programming & Support Service. InnerScope plans on launching its Self-Fitting Hearing Aids on multiple online platforms with the upcoming announcements of several retailers and on its own newly revamp NoHassleHearing.com (expected to be finished by the end of the month). In preparation for the launch, InnerScope has ramped up its inventory of its Self-Fitting Hearing Aids and Hearing Products for the anticipation of generating over five hundred thousand dollars ($500,000) to InnerScope of sales revenue for the launch. INND is well-positioned to directly benefit from the Over the Counter Hearing Aid Act which is expected to be enacted early this year. InnerScope’s Self-Fitting Hearing Aids deliver 21st Century hearing aid technology right to everyone’s fingertips just by using their smartphone at an affordable price. InnerScope’s Self-Fitting Hearing Aids empowers the user to take full control of their hearing health needs. InnerScope believes the solid foundation the Company has built over the last three years puts them in a prime position to be a leader in the emerging DTC/OTC hearing aid market. With InnerScope’s current and upcoming retail distribution/vendor sales channels producing consistent and ongoing revenue growth.  We will be updating on INND when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with INND.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in INND either long or short and we have not been compensated for this article

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

4 days ago

on

June 4, 2023

By

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by 3D Animation Production Company from Pixabay

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

1 week ago

on

May 29, 2023

By

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

3 weeks ago

on

May 19, 2023

By

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.